The FDA's Compounded Pet Medication Recall Is More Serious Than It Sounds
On November 10, 2026, the FDA's Center for Veterinary Medicine, working alongside Cornell University College of Veterinary Medicine, issued an urgent advisory that a lot of dog owners probably scrolled past. Compounded medications, the custom-mixed prescriptions that vets order when a standard drug isn't quite right for a specific dog, are failing potency tests. Seizure therapies, antibiotics, ear preparations. The ones your dog might be on right now.
The advisory isn't a minor procedural notice. Potency failures cut both ways: a dose that's weaker than it should be leaves your dog under-medicated, which matters a lot if that medication is controlling epileptic seizures or clearing a serious infection. A dose that's stronger than it should be can tip into toxicity. Neither outcome announces itself with a label change. The bottle looks exactly the same.
What Compounded Medications Actually Are
Compounded drugs aren't the same as standard licensed products from a pharmacy. A compounded medication is mixed specifically for your dog, often because:
- the commercially available drug comes in a strength that doesn't suit a small or unusually large dog
- your dog needs a different formulation (a flavoured liquid instead of a tablet, for instance)
- the licensed version is on backorder
Vets reach for compounding regularly, and for good reason. The problem is that compounded products don't go through the same pre-approval process as licensed drugs. Quality control sits with the compounding pharmacy, and that's where the November advisory is pointing its finger.
The FDA hasn't released a single named pharmacy at the time of writing, which is frustrating but probably deliberate while the investigation is ongoing. What Cornell's veterinary team emphasised is that the failures span multiple drug types, not a single batch from a single supplier. That's the part worth taking seriously.
Which Medications Are Under the Most Scrutiny
The advisory specifically calls out three categories.
Seizure therapies are the most urgent concern. Phenobarbital and potassium bromide are both commonly compounded for dogs with epilepsy, and therapeutic window management for seizure drugs is already tricky under ideal circumstances. A batch running at 70% stated potency could mean a dog that was previously stable starts seizing again. A batch running at 130% could cause sedation, ataxia, or worse.
Antibiotics are the second category. Under-potent antibiotics don't just fail to clear an infection, they create conditions for antibiotic resistance to develop. This is bad enough in a human context; in a dog that's already immunocompromised or recovering from surgery, it's a real clinical risk.
Ear preparations round out the list. These are easier to overlook because ear infections feel less dramatic than seizures, but a topical otic medication with inconsistent active ingredient concentration can let a bacterial or yeast infection persist and deepen, sometimes progressing to middle-ear involvement.
What to Actually Do Right Now
Check whether your dog is on any compounded medication. If you're not sure, look at the label. Licensed products from recognised manufacturers will typically state the manufacturer clearly. A compounded prescription will usually name the compounding pharmacy.
If your dog is on a compounded seizure medication, call your vet today rather than waiting. Don't stop the medication before speaking to your vet. Abruptly discontinuing seizure medication is dangerous, potentially more immediately dangerous than a potency variation. Your vet may want to run a serum drug level check, which is a blood test that tells you the actual concentration of the drug in your dog's system rather than relying on what the label claims.
For antibiotics, the question to ask your vet is whether a licensed alternative exists. In many cases it does, and switching temporarily while the advisory plays out is straightforward.
Ear preparations are worth raising at your next appointment if your dog's ear condition hasn't been responding as well as expected. That lack of response might have an explanation now.
The Behaviour Connection Most Owners Miss
One thing the Cornell advisory touches on, and that gets underplayed in the coverage, is that potency failures often show up as behaviour changes before they show up as obvious medical symptoms.
A dog whose seizure medication has dropped in potency might show increased anxiety, unusual startle responses, or brief focal seizures that look like odd behavioural episodes, staring, lip-smacking, sudden fear, before a full seizure occurs. Owners frequently attribute these to stress or ageing rather than a medication problem.
This is where tracking actually matters. If you're logging your dog's behaviour over time, whether through a platform like Tailo or even a basic written diary, you have something to show your vet when you call. "He's been having these episodes roughly twice a week for the past three weeks" is a different conversation from "something seems off lately". The former gets taken seriously faster.
The Broader Problem With Compounding Oversight
This isn't the first time the FDA has flagged compounded veterinary drugs. There were similar warnings in 2019 and 2022, and the gap in regulatory coverage hasn't really narrowed. The FDA can inspect compounding pharmacies, but the pre-approval requirement that governs licensed drugs simply doesn't apply to compounded products.
That's a structural gap, not an individual pharmacy failing. The November advisory is a consequence of it.
If you use compounded medications for your dog long-term, it's worth asking your vet periodically whether a licensed equivalent has become available. Manufacturers and drug availability change. What required compounding two years ago might not today.
And if your dog's condition has seemed harder to manage recently, that's a reasonable question to bring to your next appointment.
tailo